Big pharma, M&A

Watson becomes Actavis in a much talked M&A deal

Posted on 19 October 2012

Tags: , , ,

Watson Pharmaceuticals agreed to sell rights to 18 drugs to win approval from the U.S. Federal Trade Commission for its m&a of Actavis Inc.
Watson and Actavis will sell the rights to Sandoz International GmbH and Par Pharmaceuticals Inc. and give up manufacturing and marketing rights to three other medicines to resolve competition concerns, the FTC said in a statement today.

Watson completed the acquisition of closely held Actavis for 4.25 billion euros ($5.5 billion) to create the third-largest global generic-drug maker in a striking M&A deal.

For further deal information visit Current Agreements (subscription required)

 

Related

Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary

Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies

Report: Practical Guide to Finding Partners

Report: Partnering Deals and Alliances with Big Pharma

Report: Partnering Deals and Alliances with Actavis (formerly Watson Pharmaceuticals)

Report: Merger and Acquisition Terms and Agreements

Related reports:  Bigpharma Partnering Yearbook 2013

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply